ANTIBODIES AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF EPSTEIN-BARR VIRUS INFECTION: Collaboration and Licensing Opportunity

Scientists at the NIAID are developing neutralizing antibodies, originally isolated from humans or non-human primates, that could be useful in preventing primary infection or reactivation of EBV in immunocompromised individuals. These antibodies are 10-100 times more potent than the most potent EBV neutralizing antibody identified to date (72A1).

According to the World Health Organization, over 90% of the worldwide population is infected with Epstein-Barr virus by adulthood.  In most cases, the disease accompanying initial infection is subclinical though some individuals who are infected as adolescents or adults do experience infectious mononucleosis.  However, once infected, individuals carry latent EBV for their remaining lifespan.  In such individuals, immune suppression can result in reactivation of the EBV and consequently, EBV-associated lymphoproliferative disease.  Currently, there is no prophylactic to prevent primary EBV infection and additional therapeutics would be useful to treat EBV-associated B-cell driven lymphoproliferative disease.

Scientists at the NIAID are developing neutralizing antibodies, originally isolated from humans or non-human primates, that could be useful in preventing primary infection or reactivation of EBV in immunocompromised individuals.  These antibodies are 10-100 times more potent than the most potent EBV neutralizing antibody identified to date (72A1).   The antibodies target epitopes on either the gp350 surface glycoprotein of EBV or the gH/gL heterodimer.  In vitro experiments have demonstrated that the antibodies effectively inhibit EBV infection of B cells and epithelial cells as well as cell-to-cell fusion of cells expressing the viral proteins gH/gL.

Potential Commercial Applications: 

  • Treatment of individuals with compromised immune systems to prevent EBV-associated lymphoproliferative diseases

  • Prevention of primary EBV infection in individuals with compromised immune systems to prevent EBV-associated lymphoproliferative diseases

Competitive Advantages: 

  • No EBV therapeutics or prophylactics currently exist

Development Stage:

  • In vitro

Inventors:  Masaru Kanekiyo (NIAID), W. Gordon Joyce (WRAIR), Wei Bu (NIAID), Jeffrey Cohen (NIAID)

Intellectual Property:  U.S. Provisional Patent Application No. 62/490,023 filed April 25, 2017 (Pending); PCT Application No. PCT/US2018/29463 filed April 25, 2018;

U.S. Provisional Patent Application No. 62/665,977 filed May 2, 2018.

Collaborative Research Opportunity:  The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize Epstein-Barr monoclonal antibody technologies.  For collaboration and licensing  opportunities, please contact Dr. Amy Petrik, 240-627-3721; amy.petrik@nih.gov.

 


Go to the profile of NIAID Technology Transfer and Intellectual Property Office

NIAID Technology Transfer and Intellectual Property Office

NIAID’s technology transfer office, TTIPO, is a one-stop resource for organizations interested in partnering with NIAID to access, develop, and manage the translation of research discoveries into medically beneficial products. TTIPO seeks to expand NIAID’s innovation pipeline with existing and new partners in areas such as newly emerging and re-emerging infectious diseases (e.g., dengue, Zika, Ebola, influenza, methicillin-resistant Staphylococcus aureus and HIV/AIDS), biodefense (e.g., smallpox and anthrax), and immune-mediated diseases (e.g., asthma and allergy).

No comments yet.